NasdaqGS:CSWC
NasdaqGS:CSWCCapital Markets

Does CSWC’s Leadership Promotion and Insider Buying Hint at a Deeper Capital Return Strategy Shift?

Capital Southwest Corporation recently announced it had promoted Grant Eason, a 15-year credit underwriting veteran with nearly seven years at the firm, to Managing Director, highlighting continuity in its middle-market lending leadership. This leadership expansion coincides with revenue growth, a strong earnings outlook, ongoing insider share purchases, and affirmed plus special dividends that collectively reinforce investor focus on Capital Southwest’s execution and capital return...
NYSE:ROG
NYSE:ROGElectronic

Rogers (ROG) Valuation Check as Revenue and Profitability Continue to Slide Over Recent Years

Rogers (ROG) is back on investors’ radar after a stretch of weakening fundamentals, with customers delaying orders, revenue sliding about 7% a year, and profitability metrics trending the wrong way. See our latest analysis for Rogers. Even with fundamentals under pressure, Rogers' latest share price of $87.39 and a roughly 4% 3 month share price return suggest sentiment has stabilized a bit. However, the roughly 18% 1 year total shareholder return loss shows long term momentum is still...
NasdaqCM:YIBO
NasdaqCM:YIBOCommercial Services

3 Promising Penny Stocks With Market Caps Under $200M

Major stock indexes in the United States are currently exhibiting mixed performance as investors await the Federal Reserve's decision on interest rates, which could significantly impact market dynamics. In this context, penny stocks—an older term for shares of smaller or less-established companies—remain a relevant area for exploration. By focusing on those with strong financials and potential growth trajectories, investors can uncover opportunities that might offer both stability and upside...
NYSE:LXFR
NYSE:LXFRMachinery

Discovering US Undiscovered Gems December 2025

As the Federal Reserve's anticipated rate cut looms, the U.S. stock market presents a mixed picture with major indices showing varied performances. Amidst this backdrop, small-cap stocks have gained attention for their potential to outperform in a declining interest-rate environment, offering investors opportunities to uncover lesser-known companies poised for growth. In such conditions, identifying stocks with strong fundamentals and resilience becomes crucial for those seeking undiscovered...
NYSE:RYN
NYSE:RYNSpecialized REITs

Three Dividend Stocks To Enhance Your Portfolio

As the U.S. market navigates mixed signals ahead of a crucial Federal Reserve decision on interest rates, investors are keenly observing how these changes might impact their portfolios. In such an environment, dividend stocks can offer a stable income stream and potential for growth, making them a valuable consideration for those looking to enhance their investment strategy amidst fluctuating economic conditions.
NYSE:YEXT
NYSE:YEXTSoftware

Yext (YEXT) Earnings: Sustained Profitability Challenges Skeptics of Margin-Driven Growth Story

Yext (YEXT) has just posted its Q3 2026 numbers, with revenue of about $112 million and basic EPS of roughly $0.05 as the company continues to build on the profitability it achieved over the last year. The company has seen quarterly revenue hover around the low $100 million mark over recent periods, from $113.1 million in Q4 2025 to $109.5 million in Q1 2026 and $113.1 million in Q2 2026. EPS has swung from a loss of about $0.06 in Q4 2025 to positive $0.22 in Q2 2026 and stayed in the black...
NYSE:CON
NYSE:CONHealthcare

Is Concentra Group Holdings Parent (CON) Quietly Repositioning Around Telemed With Its New Corona Clinic?

Concentra Group Holdings Parent recently opened Concentra Corona, a new occupational health medical center at 629 North Main Street, Unit C-3, Corona, California, offering work injury care, physical therapy, drug testing, DOT physicals, pre-placement exams, and employer-focused telemedicine services. This expansion deepens Concentra’s California footprint and highlights how its proprietary Concentra Telemed platform is being integrated alongside brick‑and‑mortar clinics to support employer...
NasdaqGS:ATEC
NasdaqGS:ATECMedical Equipment

Is Alphatec Holdings Still Attractive After Its 128% 2025 Surge?

If you are wondering whether Alphatec Holdings at around $20.67 is still a smart buy after its huge run, or if the easy money has already been made, you are not alone. The stock has slipped 2.6% over the last week but is still up 2.1% over 30 days, with an eye catching 128.1% gain year to date and 113.3% over the past year. This naturally raises questions about how much upside is left. Investors have been reacting to a stream of positive updates around Alphatec's expanding spine surgery...
NasdaqGS:BPOP
NasdaqGS:BPOPBanks

Has Popular’s 143% Five Year Surge Already Priced In Its Future Returns?

If you have been wondering whether Popular is still a buy after its big multi year run, you are not alone. This article will walk through what the current share price is really baking in. The stock has slipped about 0.6% over the last week but remains up 1.0% over the past month, with a strong 25.7% gain year to date and a hefty 142.7% return over five years that suggests the market has steadily been repricing its prospects. Recent headlines have focused on Popular's positioning in Puerto...
NasdaqGS:CNXC
NasdaqGS:CNXCProfessional Services

Is Concentrix Now an Opportunity After a 67.8% Three Year Share Price Slide?

If you have been wondering whether Concentrix is a beaten down bargain or a value trap, you are not alone. This article will walk through the numbers in plain English. The stock has bounced recently, up 3.2% over the last week and 10.4% over the past month, even though it is still down 12.5% year to date and 11.3% over the last year. Over a longer horizon, it has seen a much steeper 67.8% slide over three years and 59.0% over five. That kind of whiplash performance has been shaped by...
NYSE:AM
NYSE:AMOil and Gas

Has the Market Already Priced In Antero Midstream’s Strong Multi Year Share Price Run?

Wondering if Antero Midstream is still a good buy after its run up, or if most of the easy money has already been made? In this article, we break down what the market is really pricing in here. The stock has climbed to around $18.58, delivering roughly 4.6% over the last week, 4.9% over the past month, 20.0% year to date and 30.5% over the last year, with a 109.6% gain over three years and 235.0% over five years. Those moves have come as midstream energy names like Antero have benefited from...
NasdaqGS:SLM
NasdaqGS:SLMConsumer Finance

Is SLM Offering Long Term Value After Recent Share Price Weakness?

Wondering if SLM is quietly trading below what it is really worth? You are not alone. This stock has been catching the eye of investors hunting for mispriced financial names. Despite a choppy ride in the short term, with the share price down 12.8% over the last week and 4.1% year to date, the longer term story still shows gains of 68.1% over 3 years and 138.6% over 5 years. Recent market moves have come as investors reassess student loan and consumer credit exposure in a higher rate...
NasdaqGS:CLOV
NasdaqGS:CLOVHealthcare

Will Contract Wins And Rising EPS Quality Change Clover Health Investments' (CLOV) Technology-Led Narrative?

Clover Health Investments recently reported winning new contracts, supported by an average 10.3% increase in its customer base over the past two years. Earnings per share have compounded at a very large annual rate while cash burn has steadily reduced, pointing to improving operational self-sufficiency. Now we’ll explore how these contract wins and improving earnings quality might reshape Clover Health’s existing technology-focused investment narrative. Trump has pledged to "unleash"...
NasdaqGS:APLS
NasdaqGS:APLSBiotechs

Is Apellis Pharmaceuticals (APLS) Undervalued After Its Recent Share Price Rebound?

Apellis Pharmaceuticals (APLS) has quietly staged a rebound this month, with the stock up roughly 23% even as its past year performance remains weak, inviting a closer look at what might be changing. See our latest analysis for Apellis Pharmaceuticals. The 23.5% 1 month share price return has helped Apellis claw back some ground from a difficult stretch. However, the 1 year total shareholder return remains deep in negative territory, which suggests sentiment may be stabilising rather than...
NasdaqGS:UMBF
NasdaqGS:UMBFBanks

Does UMB Financial’s Valuation Reflect Its Excess Returns Amid Regional Banking Uncertainty?

If you are wondering whether UMB Financial is quietly trading at a discount or already priced for perfection, you are not alone. This stock has been drawing attention from investors hunting for value in regional banks. Despite some short-term noise, the share price is up 3.4% over the last month and 1.9% year to date, though it is still down 7.5% over the past year after a strong multiyear climb of 50.8% over three years and 79.4% over five years. Recent headlines around the regional banking...
NasdaqGS:SLDP
NasdaqGS:SLDPAuto Components

How Insider Selling and New Severance Terms Will Impact Solid Power (SLDP) Investors

In recent days, Solid Power disclosed that director Erik Anderson sold 30,000 shares and the company amended its Executive Change in Control and Severance Plan, reshaping how senior leaders could be compensated if control changes occur. These governance moves, coming alongside continued discussion of losses and negative cash flow despite high-profile partnerships and government backing, spotlight the tension between Solid Power’s technological promise and its financial strain. Next, we’ll...
NasdaqGS:ORLY
NasdaqGS:ORLYSpecialty Retail

Is It Too Late To Consider O'Reilly Automotive After Its Strong Multi Year Rally?

If you are wondering whether O'Reilly Automotive is still attractive after its long run higher, or if the easy money has already been made, you are not alone. This breakdown is designed to cut through the noise and focus on what the stock may really be worth. Even after a recent pullback of about 4.4% over the last week and 3.9% over the last month, the stock is still up 19.0% year to date and 11.4% over the past year. That caps off a multi year climb of 73.6% in three years and 210.7% in...
NYSE:PVH
NYSE:PVHLuxury

Has PVH’s 27% 2025 Slide Created a Value Opportunity for Investors?

If you are wondering whether PVH is starting to look like a bargain after a rough stretch or if it is cheap for a reason, you are not alone. This is exactly the kind of setup where valuation work really matters. The stock has slipped to around $76.12 after a 13.1% drop over the last week and is now down 27.4% year to date and 30.5% over the last year, shifting many investors from growth optimism to value hunting mode. Recent market chatter has focused on how PVH is navigating a tougher...
NasdaqGS:FCFS
NasdaqGS:FCFSConsumer Finance

What FirstCash Holdings (FCFS)'s Broad-Based Earnings Upside Means For Shareholders

Earlier this week, FirstCash Holdings reported a very strong quarter, with accelerating revenue growth and higher earnings across its U.S. and Latin American pawn businesses, complemented by an incremental boost from its newly acquired H&T pawn stores in the U.K. The company also highlighted broad-based strength at American First Finance, where lower loss provisions and improved operating margins drove substantial earnings growth in its retail point-of-sale payment solutions segment. Next,...